Fibrosarcoma - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Fibrosarcoma - Pipeline Review, H2 2015’, provides an overview of the Fibrosarcoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Fibrosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosarcoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Fibrosarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Fibrosarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Fibrosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Fibrosarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Fibrosarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Fibrosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Fibrosarcoma Overview 6
Therapeutics Development 7
Pipeline Products for Fibrosarcoma - Overview 7
Pipeline Products for Fibrosarcoma - Comparative Analysis 8
Fibrosarcoma - Therapeutics under Development by Companies 9
Fibrosarcoma - Therapeutics under Investigation by Universities/Institutes 10
Fibrosarcoma - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Fibrosarcoma - Products under Development by Companies 13
Fibrosarcoma - Products under Investigation by Universities/Institutes 14
Fibrosarcoma - Companies Involved in Therapeutics Development 15
Advanced Proteome Therapeutics Corporation 15
Novartis AG 16
Plexxikon Inc. 17
Rigontec GmbH 18
Siena Biotech S.p.A. 19
Sumitomo Dainippon Pharma Co., Ltd. 20
Fibrosarcoma - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 27
Drug Profiles 29
APC-103 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
DSR-6434 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
everolimus - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ImOl-100 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
KRA-0008 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
LK-3 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
MAT-303 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
PLX-7486 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
SEN-461 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Fibrosarcoma - Recent Pipeline Updates 43
Fibrosarcoma - Dormant Projects 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50
List Of Tables
Number of Products under Development for Fibrosarcoma, H2 2015 7
Number of Products under Development for Fibrosarcoma - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Products under Investigation by Universities/Institutes, H2 2015 14
Fibrosarcoma - Pipeline by Advanced Proteome Therapeutics Corporation, H2 2015 15
Fibrosarcoma - Pipeline by Novartis AG, H2 2015 16
Fibrosarcoma - Pipeline by Plexxikon Inc., H2 2015 17
Fibrosarcoma - Pipeline by Rigontec GmbH, H2 2015 18
Fibrosarcoma - Pipeline by Siena Biotech S.p.A., H2 2015 19
Fibrosarcoma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 20
Assessment by Monotherapy Products, H2 2015 21
Number of Products by Stage and Target, H2 2015 23
Number of Products by Stage and Mechanism of Action, H2 2015 25
Number of Products by Stage and Route of Administration, H2 2015 26
Number of Products by Stage and Molecule Type, H2 2015 28
Fibrosarcoma Therapeutics - Recent Pipeline Updates, H2 2015 43
Fibrosarcoma - Dormant Projects, H2 2015 48
List Of Figures
Number of Products under Development for Fibrosarcoma, H2 2015 7
Number of Products under Development for Fibrosarcoma - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Products, H2 2015 12
Assessment by Monotherapy Products, H2 2015 21
Number of Products by Top 10 Targets, H2 2015 22
Number of Products by Stage and Top 10 Targets, H2 2015 22
Number of Products by Top 10 Mechanism of Actions, H2 2015 24
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 24
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 26
Number of Products by Top 10 Molecule Types, H2 2015 27
Number of Products by Stage and Top 10 Molecule Types, H2 2015 27
